Literature DB >> 11005273

The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production.

M Luster1, W Reinhardt, C Korber, M Lassmann, H Haenscheid, U Michalowski, J Rendl, E Eising, K Mann, C Reiners.   

Abstract

We present a case of a patient suffering from metastatic differentiated thyroid carcinoma (DTC) and insufficient endogenous TSH production suspicious of secondary hypothyroidism. The use of recombinant human TSH (rhTSH) enabled us to administer a therapeutic activity of radioactive iodine (RAI) under maximal TSH-stimulation, achieving a marked decrease in thyroglobulin accompanied by a clinical improvement.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11005273     DOI： 10.1007/BF03343758

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  10 in total

1.  Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone.

Authors:  A Z Rudavsky; L M Freeman
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

2.  Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis.

Authors:  J H Risse; F Grünwald; H Bender; H Schüller; D Van Roost; H J Biersack
Journal:  Thyroid       Date:  1999-12       Impact factor: 6.568

3.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

Authors:  P W Ladenson; L E Braverman; E L Mazzaferri; F Brucker-Davis; D S Cooper; J R Garber; F E Wondisford; T F Davies; L J DeGroot; G H Daniels; D S Ross; B D Weintraub
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

4.  Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.

Authors:  M D Ringel; P W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  1996-05       Impact factor: 5.958

5.  Thyroid carcinoma metastatic to pituitary.

Authors:  J J Sziklas; J Mathews; R P Spencer; R J Rosenberg; M T Ergin; B F Bower
Journal:  J Nucl Med       Date:  1985-09       Impact factor: 10.057

6.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.

Authors:  B R Haugen; F Pacini; C Reiners; M Schlumberger; P W Ladenson; S I Sherman; D S Cooper; K E Graham; L E Braverman; M C Skarulis; T F Davies; L J DeGroot; E L Mazzaferri; G H Daniels; D S Ross; M Luster; M H Samuels; D V Becker; H R Maxon; R R Cavalieri; C A Spencer; K McEllin; B D Weintraub; E C Ridgway
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

7.  Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects.

Authors:  L Ramirez; L E Braverman; B White; C H Emerson
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

Review 8.  Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131.

Authors:  C Reiners; M Luster; M Lassmann
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

Review 9.  Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.

Authors:  P Perros
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

10.  Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).

Authors:  C A Meier; L E Braverman; S A Ebner; I Veronikis; G H Daniels; D S Ross; D J Deraska; T F Davies; M Valentine; L J DeGroot
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958
  10 in total
  5 in total

1.  Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.

Authors:  G Berg; G Lindstedt; M Suurküla; S Jansson
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

Review 2.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

3.  Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.

Authors:  Barbara Jarzab; Daria Handkiewicz-Junak; Józef Roskosz; Zbigniew Puch; Zbigniew Wygoda; Aleksandra Kukulska; Beata Jurecka-Lubieniecka; Kornelia Hasse-Lazar; Maria Turska; Aleksander Zajusz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-29       Impact factor: 9.236

4.  Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy.

Authors:  Bart de Keizer; Boudewijn Brans; Anne Hoekstra; Pierre M J Zelissen; Hans P F Koppeschaar; Cees J M Lips; Peter P van Rijk; Rudi A Dierckx; John M H de Klerk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-12-19       Impact factor: 9.236

5.  Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration.

Authors:  Seung Hyun Son; Sang-Woo Lee; Ji-Hoon Jung; Choon-Young Kim; Do-Hoon Kim; Shin Young Jeong; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.